{
    "nctId": "NCT00956813",
    "briefTitle": "Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy",
    "officialTitle": "Phase III, Randomized, Placebo-controlled, Double-Blind Trial of Flaxseed for the Treatment of Hot Flashes",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Hot Flashes, Menopausal Symptoms, Unspecified Adult Solid Tumor, Protocol Specific",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 210,
    "primaryOutcomeMeasure": "To Evaluate the Efficacy of Flaxseed on Hot Flash Scores in Women as Measured by a Daily Prospective Hot Flash Diary.",
    "eligibilityCriteria": "* Bothersome hot flashes, defined by their occurrence \u2265 28 times per week and of sufficient severity to make the patient desire therapeutic intervention\n\n  * Presence of hot flashes for \u2265 1 month\n* Meets 1 of the following criteria:\n\n  * History of breast cancer or other cancer (currently without malignant disease)\n  * No history of breast cancer and wishes to avoid estrogen due to a perceived increased risk of breast cancer\n* Hormone receptor status not specified\n* Postmenopausal as defined by 1 of the following\\*:\n\nNOTE: \\*Women with \u2265 1 ovary but without a uterus should be deemed postmenopausal by either age \\> 55 OR a combination of estrogen within a postmenopausal range (per local lab) and follicle-stimulating hormone \\> 40 mIU/mL\n\n* Absence of a period in the past 12 months\n* Bilateral oophorectomy\n\n  * ECOG performance status 0-1\n  * Life expectancy \u2265 6 months\n  * Able to complete questionnaire(s) alone or with assistance\n  * No diabetes requiring oral or injectable antihyperglycemics\n  * No hypotension\n  * No history of allergic or other adverse reaction to flaxseed\n  * No irritable bowel syndrome, colitis, Crohn disease, or any gastrointestinal condition where the patient should not consume and/or has an intolerance/allergies to seeds or nuts\n  * At least 4 weeks since prior and no concurrent or planned androgens, estrogens, or progestational agents\n* Tamoxifen, raloxifene, or aromatase inhibitors are allowed provided the patient has been on a constant dose for \u2265 4 weeks and is not expected to stop the medication during study treatment\n\n  \u2022 At least 4 weeks since prior and no concurrent anti-cancer therapies of any kind\n* Trastuzumab allowed\n\n  * No concurrent treatment with other anti-cancer therapies of any kind except for trastuzumab or endocrine therapies\n  * No concurrent (\u2264 7 days prior to registration) or planned use of other agents for treating hot flashes (i.e., gabapentin, clonidine, antidepressants, estrogen treatment, megestrol acetate, or Bellergal)\n* Stable dose of vitamin E (as a general vitamin supplement) allowed provided it is \u2264 800 IU/day, it was started \\> 30 days before study initiation, and is to be continued through study period\n* Patients who have been using antidepressants for mood and have been on a stable dose for over a month and meet the eligibility criteria for hot flash frequency and duration are eligible\n\n  \u2022 No concurrent anticoagulants or anti-platelets (1 mg of Coumadin for central line patency allowed)\n* Aspirin allowed (\u2264 81 mg)\n\n  * No concurrent anti-hypertensives\n  * No other concurrent herbal supplements for any reason, including soy and soy supplements (i.e., powders, pills, or milk)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}